刘李，男，中共党员，博士，教授，博士研究生导师，江苏省“青蓝工程”学术带头人、“333工程”第三层次和“六大人才高峰”培养对象。现任中国药科大学药学院药理系教师。
一、研究方向
专业方向为药物代谢动力学，具体研究方向为：疾病状态下代谢酶和转运体功能与表达调控及其对物质代谢影响。近5年共发表相关SCI论文30余篇，培养硕士研究生13人，博士研究生3人。另外在创新药物药物代谢动力学和生理药物代谢动力学模型方面具有研究特色。
二、教学情况
现为本科生《药物代谢动力学》理论和实验课程负责人，年均学时数215，独立指导本科实习生20人，主持校级教改课题2项，指导国家级大学生创新项目3项，参编教材《药物代谢动力教程》。
三、教学成果
1. 2017年江苏省教学成果二等奖(4/5)
2. 2016年第一届全国医药院校实验教学改革大赛一等奖(1/4)
3. 2012年江苏省普通高等学校本专科优秀毕业设计（论文）三等奖(2/2)
4. 2016年度校级教学成果三等奖（1/4）和校级教学成果一等奖（4/6）
5. 2016年度药学院“博瑞教学奖”优秀青年教师
四、科研情况
1. 主持国家自然科学基金3项和省自然科学基金（2016年面上项目）1项。
2. 主持制药企业创新药物研究合作项目6项。
五、论文情况
近5年共发表相关SCI论文30篇，其中Web of Science 分区Q1杂志共计7篇，同时也有部分研究工作发表在药代动力学领域权威期刊如Drug Metabolism and Disposition, Biochemical Pharmacology 和Clinical Pharmacokinetics。
六、代表性论文（*通讯作者）
1. Chen Y,Zhao K,Liu F,Li Y,Zhong Z,Hong S,Liu X*,Liu L*. Predicting Antitumor Effect ofDeoxypodophyllotoxinin NCI-H460 Tumor-Bearing Mice on the Basis of In Vitro Pharmacodynamics and a Physiologically Based Pharmacokinetic-Pharmacodynamic Model. Drug Metab Dispos.2018 Jun; 46(6): 897-907.
2. Xu J,Zhang M,Zhang X,Yang H,Sun B,Wang Z,Zhou Y,Wang S,Liu X*,Liu L*. Contribution of Hepatic Retinaldehyde Dehydrogenase Induction to Impairment of Glucose Metabolism by High-Fat-Diet Feeding in C57BL/6J Mice. Basic Clin Pharmacol Toxicol.2018 May 12. doi: 10.1111/bcpt.13039.
3. Sun B,Zhong Z,Wang F,Xu J,Xu F,Kong W,Ling Z,Shu N,Li Y,Wu T,Zhang M,Zhu L,Liu X*,Liu L*. Atorvastatin impaired glucose metabolism in C2C12 cells partly via inhibiting cholesterol-dependent glucose transporter 4 translocation. Biochem Pharmacol.2018; 150:108-119.
4. Liu L, Miao M, Chen Y, Wang Z, Sun B, Liu X*. Altered function and expression of ABC transporters at the blood–brain barrier and increased brain distribution of phenobarbital in acute liver failure mice. Front Pharmacol. 2018; 9:190. doi: 10.3389/fphar.2018.00190
5. Wang F,Miao MX,Sun BB,Wang ZJ,Tang XG,Chen Y,Zhao KJ,Liu XD*,Liu L*. Acute liver failure enhances oral plasma exposure of zidovudine in rats by downregulation of hepatic UGT2B7 and intestinal P-gp. Acta Pharmacol Sin.2017 Aug 3. doi: 10.1038/aps.2017.54.
6. Chen Y, Zhao K, Liu F, Xie Q, Zhong Z, Miao M, Liu X*, Liu L*. Prediction of Deoxypodophyllotoxin Disposition in Mouse, Rat, Monkey, and Dog by Physiologically Based Pharmacokinetic Model and the Extrapolation to Human. Front Pharmacol. 2016 Dec 16; 7:488. doi: 10.3389/fphar.2016.00488.
7. Shu N,Hu M,Ling Z,Liu P,Wang F,Xu P,Zhong Z,Sun B,Zhang M,Li F,Xie Q,Liu X*,Liu L*. The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3aandSLCO1B1. Sci Rep.2016 Sep 14;6:33072. doi: 10.1038/srep33072.
8. Liu L, Miao M, Zhong Z, Xu P, Chen Y, Liu X*. Chronic administration of caderofloxacin, a new fluoroquinolone, increases hepatic CYP2E1 expression and activity in rats. Acta Pharmacol Sin. 2016; 37(4): 561-70.
9. Ling Z, Shu N, Xu P, Wang F, Zhong Z, Sun B, Li F, Zhang M, Zhao K, Tang X, Wang Z, Zhu L, Liu L*, Liu X*. Involvement of pregnane X receptor in the impaired glucose utilization induced by atorvastatin in hepatocytes. Biochem Pharmacol. 2016; 100: 98-111.
10. Liu C, Hu M, Guo H, Zhang M, Zhang J, Li F, Zhong Z, Chen Y, Li Y, Xu P, Li J, Liu L*, Liu X*. Combined Contribution of Increased Intestinal Permeability and Inhibited Deglycosylation of Ginsenoside Rb1 inIntestinal Tract to the Enhancement of Ginsenoside Rb1 Exposure in Diabetic Rats Following Oral Administration. Drug Metab Dispos. 2015; 43(11): 1702-10.
11. Li J, Guo HF, Liu C, Zhong Z, Liu L*, Liu XD*. Prediction of Drug Disposition in Diabetic Patients by Means of a Physiologically Based Pharmacokinetic Model. Clin Pharmacokinet. 2015; 54(2):179-93.
12. Liu L, Liu XD*. Alterations in function and expression of ABC transporters at blood-brain barrier under diabetes and the clinical significances. Front Pharmacol. 2014; 5: 273.
七、联系方式
(1) 电话：
(2) 手机：**
(3) E-mail：liulee@yeah.net